RAS and EF-hand domain containingGenealiases: RAB45 · TSG
Q-omics provides the consensus-scored RASEF profile across patient tissues and cancer cell-line models. RASEF expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RASEF is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RASEF RNA expression shows 18,701 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where RASEF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASEF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASEF survival associations across molecular data types. RASEF RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASEF RNA expression–survival associations across cancer types. High RASEF expression shows unfavorable associations in LGG, UVM, KICH, KIRP and LUSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RASEF RNA expression.
This table summarizes RASEF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RASEF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASEF shows lower tumor expression in THCA and LUSC and higher tumor expression in LIHC, UCEC, BRCA and BLCA. The THCA box plot shows higher RASEF RNA expression in normal versus tumor tissue (log2 FC = −0.882, t-test p < 0.001).
This table shows molecular features associated with RASEF in patient tissues and cancer cell lines. In patient samples, RASEF shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RASEF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
